Science Pool

Understanding the Hepatotoxicity of Fasiglifam (TAK-875)

Fasiglifam (TAK-875) is a GPR40 agonist which was developed for the treatment of type 2 diabetes. However, during Phase III clinical trials, it was withdrawn due to adverse liver effects.

In this poster, we focus on:

  • deciphering the mechanism of hepatotoxicity of fasiglifam (TAK-875)
  • understanding the impact of plasma protein binding and mitochondrial effects by fasiglifam using the Seahorse flux analyser platform

Read our poster to learn more about our research!

Sounds interesting?
Enter your details below to continue reading…

By clicking on ‘Continue’ I agree that my data is being transferred to the Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our Privacy Policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Join our community

Discover the exclusive benefits on offer if you join our community.